{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/otitis-media-acute/prescribing-information/erythromycin/","result":{"pageContext":{"chapter":{"id":"0f55a4d8-b11d-53a6-a26e-b2a9e98e8dd8","slug":"erythromycin","fullItemName":"Erythromycin","depth":2,"htmlHeader":"<!-- begin field 93f49b5d-3be4-47b3-94a5-a91f015dacea --><h2>Erythromycin</h2><!-- end field 93f49b5d-3be4-47b3-94a5-a91f015dacea -->","summary":"","htmlStringContent":"<!-- begin item d72bfad5-ec8a-4e72-aa3e-a91f015dab7c --><!-- end item d72bfad5-ec8a-4e72-aa3e-a91f015dab7c -->","topic":{"id":"0671aacb-4e00-5bb2-8b54-aa0da27fb4ab","topicId":"009f13e7-d649-401b-8b63-061c029e67f2","topicName":"Otitis media - acute","slug":"otitis-media-acute","lastRevised":"Last revised in January 2021","chapters":[{"id":"793c7288-db92-5c67-8ef6-0ea9a20f6b09","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"0cbb536b-178c-5bea-a1c6-22c584a7e1b6","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"944570b9-0a8f-5b67-8ee8-556c3fd8a613","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"aedad1bf-9c58-57d9-9c3d-d1fa6e40ee13","slug":"changes","fullItemName":"Changes"},{"id":"7bc4152c-a9f8-5afe-bb63-2a48a86ebf0d","slug":"update","fullItemName":"Update"}]},{"id":"cd84410b-569d-58a4-8fe8-c2eaed2ead26","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"7875d022-7cbf-5961-a19e-d5987af92edc","slug":"goals","fullItemName":"Goals"},{"id":"8db5ac64-8db5-5daa-aa3c-d46caaf0abf3","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"3517d1cc-7aae-5036-81f5-ac0b590e84fd","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"4ca0ace8-77fc-5319-95e0-e983fa092ed9","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"f87cf2b3-b0ea-5485-b424-9518a3f586a2","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"e285c16b-d4ba-56b6-a3fd-3c27fc822357","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"749e39ba-56ce-5129-8e10-fef140b586c2","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"9df3117d-949e-56bb-ac40-0393fb87071a","slug":"definition","fullItemName":"Definition"},{"id":"cb42b641-fdc3-5bd6-a13a-ca2c1edd9c21","slug":"causes","fullItemName":"Causes"},{"id":"2682b3f3-3099-54c9-9c02-867b7f3350e0","slug":"prevalence","fullItemName":"Prevalence"},{"id":"a7d4a184-6baa-5ae6-baef-11eba15038e6","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"fc412f0f-261f-5fae-a125-cfeefdd5e8b3","slug":"prognosis","fullItemName":"Prognosis"},{"id":"18e296ab-cfe3-58be-bf23-aaf4a6c6f49e","slug":"complications","fullItemName":"Complications"}]},{"id":"a0da1ac3-73ef-561b-9301-a1ccdf5fd8a8","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"9e9b0e14-9f7d-5c5a-83a1-c4bfd193ba3d","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"7e76e099-c70a-5f57-b670-c0ad43913066","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"0dac3638-3899-5899-bd0e-647894c3f003","fullItemName":"Management","slug":"management","subChapters":[{"id":"35db78a7-148c-5b20-8fd7-54ea5aaba599","slug":"acute-otitis-media-initial-presentation","fullItemName":"Scenario: Acute otitis media - initial presentation"},{"id":"4d27de1d-1fe0-5438-98c0-f85415825ca5","slug":"persistent-acute-otitis-media-treatment-failure","fullItemName":"Scenario: Persistent acute otitis media - treatment failure"},{"id":"7d848f0c-bb0a-5ea7-90f2-dd99a1cbc49e","slug":"recurrent-acute-otitis-media","fullItemName":"Scenario: Recurrent acute otitis media"}]},{"id":"c8285b67-3320-54ae-8537-4c0626e3632e","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"f512abb6-f15e-5fef-9f9d-23e008c401ff","slug":"analgesia","fullItemName":"Analgesia"},{"id":"15d20ee0-531c-5230-9e41-6194bfbe3614","slug":"amoxicillin","fullItemName":"Amoxicillin"},{"id":"859385d7-8fde-5b5e-8357-c34d3500eeb7","slug":"clarithromycin","fullItemName":"Clarithromycin"},{"id":"bb1b0220-4609-5ab7-8102-e31414c36dab","slug":"co-amoxiclav","fullItemName":"Co-amoxiclav"},{"id":"0f55a4d8-b11d-53a6-a26e-b2a9e98e8dd8","slug":"erythromycin","fullItemName":"Erythromycin"}]},{"id":"f43bc1b4-a67e-5bab-b27c-d141e7483b01","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"51596c5b-15a7-547d-bdcf-f7a467961cd7","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"f91fb8f9-4942-5683-8b3d-d8edd775f700","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"c2fdf612-fff8-581e-bf78-7c9efcf08ddf","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"2bb0e3c7-8948-5401-97a7-741ffa1d4477","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"570abb9c-faad-515e-86bb-0b947414dcb9","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"5e5c540f-ce64-5768-9c46-dfde85f5364a","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"7f9af8df-6314-54fa-a769-b5bd0bd121ab","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"c8285b67-3320-54ae-8537-4c0626e3632e","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"34dbb9ac-0ff8-53ae-9a93-674c3b2d51d8","slug":"dosing-regime","fullItemName":"Dosing regime","depth":3,"htmlHeader":"<!-- begin field a7c43227-aa92-4a18-b7ff-a91f015ec9ef --><h3>Dosing regime</h3><!-- end field a7c43227-aa92-4a18-b7ff-a91f015ec9ef -->","summary":"","htmlStringContent":"<!-- begin item 25c4b258-edf8-4a2a-a8bd-a91f015eb7f7 --><!-- begin field 2e43325e-dc88-47e4-a78f-a91f015ec9ef --><ul><li><strong>The treatment duration for acute otitis media (AOM) is 5–7 days.</strong></li><li><strong>Prescribe for children:</strong><ul><li>1 month to 1 year: 125 mg four times a day or 250 mg twice a day.</li><li>2 years to 7 years: 250 mg four times a day or 500 mg twice a day.</li><li>8 years to 17 years: 250–500 mg four times a day or 500-1000 mg twice a day.</li></ul></li><li><strong>In children with severe renal impairment, </strong>the dose of erythromycin should be reduced.</li><li><strong>In adults, </strong>prescribe 250–500 mg four times a day.</li><li><strong>In adults with severe renal impairment</strong>, prescribe a maximum daily dose of 1.5 g of erythromycin.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/otitis-media-acute/references/\">ABPI, 2017b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/otitis-media-acute/references/\">BNF 75, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/otitis-media-acute/references/\">NICE, 2018a</a>]</p><!-- end field 2e43325e-dc88-47e4-a78f-a91f015ec9ef --><!-- end item 25c4b258-edf8-4a2a-a8bd-a91f015eb7f7 -->","subChapters":[]},{"id":"bfc76160-04ac-5f91-ba14-6ef4dcc34cbc","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field adaf954d-a0e2-4d1d-ad39-a91f015f2264 --><h3>Contraindications and cautions</h3><!-- end field adaf954d-a0e2-4d1d-ad39-a91f015f2264 -->","summary":"","htmlStringContent":"<!-- begin item d1145bf3-5f02-4eb6-a1e7-a91f015f2174 --><!-- begin field 81c1da86-6a2b-4dd7-a093-a91f015f2264 --><ul><li><strong>Do not prescribe e</strong><strong>rythromycin</strong> to people:<ul><li>With porphyria.</li><li>A history of QT interval prolongation or ventricular cardiac arrhythmia.</li><li>Conditions that predispose to QT interval prolongation such as electrolyte disturbances and people taking drugs that prolong the QT interval.</li></ul></li><li><strong>Prescribe erythromycin with caution in people with:</strong><ul><li>Renal impairment.</li><li>Impaired hepatic function (or people concomitantly receiving potentially hepatotoxic drugs) — erythromycin is principally excreted by the liver. </li><li>Myasthenia gravis — macrolide antibiotics may aggravate the symptoms of people with myasthenia gravis.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/otitis-media-acute/references/\">Preston, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/otitis-media-acute/references/\">ABPI, 2017b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/otitis-media-acute/references/\">BNF 75, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/otitis-media-acute/references/\">MHRA, 2020</a>]</p><!-- end field 81c1da86-6a2b-4dd7-a093-a91f015f2264 --><!-- end item d1145bf3-5f02-4eb6-a1e7-a91f015f2174 -->","subChapters":[]},{"id":"05fe5a15-664c-5110-84a8-c3c9b97b2206","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field 4d577620-7e68-42de-b722-a91f015f392c --><h3>Adverse effects</h3><!-- end field 4d577620-7e68-42de-b722-a91f015f392c -->","summary":"","htmlStringContent":"<!-- begin item a71685c0-9585-4583-bb90-a91f015f3845 --><!-- begin field 6edde287-7b82-47f8-90e7-a91f015f392c --><ul><li><strong>Nausea, vomiting, abdominal discomfort, and diarrhoea</strong> are the most common adverse effects of macrolides.<ul><li>Consider pseudomembranous colitis if a person develops diarrhoea during or after treatment with erythromycin. For more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/diarrhoea-antibiotic-associated/\">Diarrhoea - antibiotic associated</a>. </li></ul></li><li><strong>Anaphylaxis</strong> is rarely associated with erythromycin. For more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/angio-oedema-anaphylaxis/\">Angio-oedema and anaphylaxis</a>. </li><li><strong>Hepatotoxicity (including cholestatic jaundice) and rash</strong> have rarely been reported following treatment with erythromycin or clarithromycin.</li><li><strong>Reversible hearing loss (sometimes with tinnitus)</strong> can occur after large doses of erythromycin or clarithromycin.</li><li><strong>Other adverse effects reported rarely or very rarely include</strong> pancreatitis, QT interval prolongation, arrhythmias, Stevens-Johnson syndrome, and toxic epidermal necrolysis.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/otitis-media-acute/references/\">ABPI, 2017b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/otitis-media-acute/references/\">BNF 75, 2018</a>]</p><!-- end field 6edde287-7b82-47f8-90e7-a91f015f392c --><!-- end item a71685c0-9585-4583-bb90-a91f015f3845 -->","subChapters":[]},{"id":"841b1cbb-1ae7-5f4d-96b7-d336a05ee81d","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field 842857c5-757b-46cb-b4c5-a91f015f56f3 --><h3>Drug interactions</h3><!-- end field 842857c5-757b-46cb-b4c5-a91f015f56f3 -->","summary":"","htmlStringContent":"<!-- begin item 2512d5e7-8310-4b17-90d3-a91f015f566b --><!-- begin field 45040586-c598-4a10-8025-a91f015f56f3 --><ul><li><strong>Carbamazepine </strong>— erythromycin markedly increases the concentration of carbamazepine. Monitor carbamazepine levels and adjust dose.<ul><li>Advise the person to report symptoms of carbamazepine toxicity (such as nausea, vomiting, ataxia, or drowsiness).</li></ul></li><li><strong>Drugs that prolong the QT interval</strong> — particular care should be taken with these medications. The concurrent use of two or more drugs that prolong the QT interval should be avoided because of the risk of torsade de pointes arrhythmias. Seek advice from a microbiologist regarding a suitable alternative antibiotic.</li><li><strong>Drugs that cause hypokalaemia (such as diuretics, corticosteroids, short-acting beta<sub>2</sub>-agonists). </strong>Hypokalaemia is a risk factor for QT prolongation — seek advice from a microbiologist regarding a suitable alternative antibiotic.</li><li><strong>Statins</strong> — erythromycin is a potent inhibitor of liver enzyme cytochrome P450 CYP3A4, which particularly affects the metabolism of simvastatin and atorvastatin [<a class=\"bibliography-reference internal-reference\" href=\"/topics/otitis-media-acute/references/\">UKMi, 2016</a>]. <ul><li>For simvastatin — do not prescribe erythromycin to a person taking simvastatin. If treatment with clarithromycin or erythromycin cannot be avoided, stop treatment with simvastatin during the course of the treatment [<a class=\"bibliography-reference internal-reference\" href=\"/topics/otitis-media-acute/references/\">UKMi, 2016</a>].</li><li>For atorvastatin — avoid concurrent use with erythromycin. If concurrent use cannot be avoided, prescribe the lowest dose of atorvastatin, and advise the person to report any muscle pain, tenderness, or weakness or dark coloured urine [<a class=\"bibliography-reference internal-reference\" href=\"/topics/otitis-media-acute/references/\">UKMi, 2016</a>].</li><li>Other statins — fluvastatin, pravastatin and rosuvastatin are not metabolised by cytochrome P450 3A4 and studies do not suggest that fluvastatin and rosuvastatin are affected by erythromycin, although pravastatin exposure may be slightly increased by erythromycin. Until more information is available about other potential mechanisms of interaction, these drugs should be used with caution in combination with erythromycin and the person should be advised to report any muscle pain, tenderness, or weakness or dark coloured urine (signs of myopathy) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/otitis-media-acute/references/\">UKMi, 2016</a>]. </li></ul></li><li><strong>Theophylline</strong> — check theophylline levels 48 hours after starting erythromycin, and adjust the dose of theophylline accordingly.<ul><li>Erythromycin increases plasma concentrations of theophylline, and theophylline may also reduce serum concentrations of erythromycin. </li></ul></li><li><strong>Rivaroxaban </strong>— erythromycin may increase levels of rivaroxaban, increasing the risk of bleeding. </li><li><strong>Warfarin</strong> — the anticoagulant effect of warfarin may be increased by erythromycin. Monitor the international normalized ratio (INR), and adjust the warfarin dose accordingly.</li><li><strong>Calcium channel blockers (CCBs)</strong> — due to an increased risk of adverse effects such as hypotension, caution is advised with the concurrent use of erythromycin and CCBs. Monitor, and reduce the dose of CCB if adverse effects occur.</li><li><strong>Contraceptives</strong> — additional contraceptive precautions are <em>not</em> required during or after a course of clarithromycin or erythromycin.<ul><li>However, advise women on the importance of correct contraceptive practice if they experience vomiting or diarrhoea. For further information, see the section on vomiting or diarrhoea in the CKS topics on <a class=\"topic-reference external-reference\" href=\"/topics/contraception-combined-hormonal-methods/\">Contraception - combined hormonal methods</a> and <a class=\"topic-reference external-reference\" href=\"/topics/contraception-progestogen-only-methods/\">Contraception - progestogen-only methods</a>. </li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/otitis-media-acute/references/\">Preston, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/otitis-media-acute/references/\">UKMi, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/otitis-media-acute/references/\">ABPI, 2017b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/otitis-media-acute/references/\">FSRH, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/otitis-media-acute/references/\">BNF 75, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/otitis-media-acute/references/\">MHRA, 2020</a>]</p><!-- end field 45040586-c598-4a10-8025-a91f015f56f3 --><!-- end item 2512d5e7-8310-4b17-90d3-a91f015f566b -->","subChapters":[]},{"id":"3a2c06a3-0c8b-5f53-9f42-470fbc124fc4","slug":"pregnancy-breastfeeding","fullItemName":"Pregnancy and breastfeeding","depth":3,"htmlHeader":"<!-- begin field 8f753a3a-8c78-48ed-bc5d-a91f015f778e --><h3>Pregnancy and breastfeeding</h3><!-- end field 8f753a3a-8c78-48ed-bc5d-a91f015f778e -->","summary":"","htmlStringContent":"<!-- begin item c9816874-adb3-45cc-8478-a91f015f76bf --><!-- begin field 85ffef2a-b657-436e-bf36-a91f015f778e --><ul><li><strong>Pregnancy</strong><ul><li>The British National Formulary (BNF) states that erythromycin is not known to be harmful when used in pregnancy [<a class=\"bibliography-reference internal-reference\" href=\"/topics/otitis-media-acute/references/\">BNF 75, 2018</a>].  </li><li>Most studies do not suggest erythromycin use is associated with malformations or other adverse effects on the fetus, but there is an inconclusive association with cardiovascular defects and pyloric stenosis [<a class=\"bibliography-reference internal-reference\" href=\"/topics/otitis-media-acute/references/\">UKTIS, 2012</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/otitis-media-acute/references/\">ABPI, 2017b</a>].<ul><li>The manufacturer reports that animal studies have shown no hazard, and erythromycin has been reported to cross the placental barrier in humans but fetal plasma levels are generally low [<a class=\"bibliography-reference internal-reference\" href=\"/topics/otitis-media-acute/references/\">ABPI, 2017b</a>].  </li></ul></li><li>Erythromycin is the macrolide of choice because it has more documented experience and is considered to be a safe and effective antibiotic during pregnancy [<a class=\"bibliography-reference internal-reference\" href=\"/topics/otitis-media-acute/references/\">UKTIS, 2012</a>]<strong>.  </strong></li></ul></li><li><strong>Breastfeeding</strong><ul><li>Macrolides are a suitable choice during breastfeeding [<a class=\"bibliography-reference internal-reference\" href=\"/topics/otitis-media-acute/references/\">Schaefer, 2015</a>], and the BNF advises that erythromycin is not known to be harmful when used by breastfeeding women [<a class=\"bibliography-reference internal-reference\" href=\"/topics/otitis-media-acute/references/\">BNF 75, 2018</a>].  </li><li>However, the manufacturer advises that since erythromycin is passed into breast milk, caution should be exercised when it is given to a breastfeeding mother [<a class=\"bibliography-reference internal-reference\" href=\"/topics/otitis-media-acute/references/\">ABPI, 2017b</a>].  </li></ul></li></ul><!-- end field 85ffef2a-b657-436e-bf36-a91f015f778e --><!-- end item c9816874-adb3-45cc-8478-a91f015f76bf -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}